Canada Markets open in 4 hrs 12 mins

Medifocus, Inc. Submits For New Patent Titled “Thermodilatation and Thermocompression to Facilitate Targeted Cluster Tissue Ablation and Immune Response”

COLUMBIA, MD and TORONTO, ON / ACCESSWIRE / November 29, 2018 / Medifocus Inc. (OTCQB : MDFZF and TSX-V: MFS) is pleased to announce it has submitted for a new Patent Titled: "Thermodilatation and Thermocompression to Facilitate Targeted Cluster Tissue Ablation and Immune Response". This Patent Pending invention will add to Medifocus' extensive patent portfolio of already issued USA and International Patents.

This new patent was submitted on November 9, 2018 to the United States Patent and Trademark Office (USPTO). The authors of this patent are: William W. Jow M.D., Stuart E. Katz M.D., Alan J. Fenn Ph.D. and John Mon. The patent utilizes thermocompression technologies such as: Medifocus Prolieve® Transurethral Thermodilatation™ (TUTD™), Medifocus APA1000 Breast Cancer Focused Microwave Treatment device and/or other thermocompression technologies to entrap pre-implanted high electric conductive material to facilitate focused heating and/or activation of molecular therapeutics to cause Cluster Tissue Ablation. In addition, the enhanced efficiency to local focused thermotherapy will facilitate the natural immune response within the entrapped microenvironment which will further aid the ablation of both local and distant cancer sites.

Dr. William Jow, President and CEO of Medifocus Inc. added, "Filing this innovative patent is a testament to our commitment and emphasis on Focal Therapy and will further the direction of our company toward Cancer Treatments. Focal therapies are ideal for both early Prostate Cancer and early- and late-stage Breast Cancers as well as treatments of other benign and malignant lesions. This invention can potentially be used with immunotherapeutic agents such as check point inhibitors to modulate the immune response not only within the tumor microenvironment locally, but to open the pathways to distant sites. Facilitating local immune cell kill and/or weakening tumor cell defense mechanism are in line with the current trend of cancer treatments."

About The Prolieve® Thermodilatation System

The Prolieve® Thermodilatation System offers potential relief to the millions of men who suffer from Benign Prostatic Hyperplasia (BPH), a condition that becomes common as men age. About half of men over 50 have some enlargement of the prostate gland, and this rises to about 90% among those over 70. As the prostate expands, it compresses or constricts the urethra, thereby restricting the normal passage of urine. This can cause infection as well as bladder and kidney damage.

The Prolieve® system is a novel focused heat therapy product which utilizes a unique combination of "prostate directed" focused heat energy in combination with a cooled, and pressurized "dilatation balloon" to achieve immediate and long-term relief of BPH symptoms with very minimal treatment induced side effects after a 45 minute, in office out-patient procedure. The combined effect of this "heat plus compression" therapy is twofold: first, the heat denatures the proteins in the wall of the urethra, causing a stiffening of the opening created by the inflated balloon, forming a temporary biological stent. Second, the heat serves effectively to kill off prostate cells outside the wall of the urethra, thereby creating sufficient space for the enlarged natural opening.

About Medifocus, Inc.:

Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) is a Biotechnology Company with a portfolio of medical technologies that utilize patented Focal Thermal Technology to treat conditions ranging from Prostate Diseases to Breast Cancer. Its Prolieve® Thermodilatation™ System offers symptomatic relief to men with Benign Prostatic Hyperplasia (BPH) through a simple, 45-minute, in-office treatment. Prolieve® is both FDA and Medicare approved for treating symptomatic BPH with over 100,000 cases performed in the U.S. alone, and with proven long-term safety, efficacy and durability. Its APA 1000 Breast Cancer Treatment System was licensed from Massachusetts Institute of Technology and developed by the Medifocus team. The Targeted Focal Thermotherapy has been demonstrated in Phase 2 clinical trials to offer significantly better tumor shrinkage in patients treated with the combined Chemothermal therapy compared those treated with Chemotherapy alone. APA 1000 was also shown to be effective in reducing margin positivity among patients treated with such thermotherapy prior to lumpectomy.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more details, please visit:

www.medifocusinc.com

www.prolieve.com

www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company Relations: Medifocus, Inc. Tel: 410-290-5734

email to: info@medifocusinc.com

Forward-Looking Statements

This news release contains "forward-looking statements" and "forward-looking information", which may not be based on historical facts. Forward-looking statements and forward-looking information, include, but are not limited to, information and statements with respect to the benefit to Medifocus' future growth resulting from the acquisition of additional intellectual property rights, additional treatment possibilities and the expectation that sales from Prolieve® may accelerate as a consequence. Forward-looking statements are frequently characterized by words such as "plan," "expect," "project," "intend," "believe," "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Such forward-looking statements and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or forward-looking information. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements and forward-looking information. Except as required by applicable securities laws, the Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more details, please visit:

www.medifocusinc.com

www.prolieve.com

www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627

Medifocus, Inc. Tel: 410-290-5734

SOURCE: Medifocus, Inc.